DeCure for Neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language
DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Rett syndrome is a monogenetic neurodevelopmental disorder affecting roughly 1 in 10,000 live female births, caused almost exclusively by mutations in the X-linked gene MECP2. Clinical diagnosis rests on loss of acquired purposeful hand skills, development of distinctive hand stereotypies, loss of spoken language, autistic behaviours, motor dysfunctions, seizure disorders, and gait abnormalities. Brain volume is reduced, especially in the cerebral hemispheres, and multiple neurotransmitter systems are altered — acetylcholine, dopamine, serotonin, glutamate, substance P, and various trophic factors. Mecp2-mutant mice recapitulate the phenotype, showing smaller cortical neurons with higher packing density and reduced dendritic complexity, plus consistent defects in synaptic plasticity. The disorder is therefore regarded as a synaptopathy.
The natural history includes onset of hypotonia, autistic tendency, and abnormal fine finger and gross arm movements in early infancy. Symptoms appear at different ages, with regressional and static periods. Sleep studies point to early hypofunction of brainstem aminergic neurons and later hypofunction of dopaminergic neurons followed by receptor supersensitivity. The pathophysiology suggests that early aminergic hypofunction interferes with the development of higher neuronal systems. Locomotive dysfunction correlates with language disability, and stereotypy correlates with regression of higher cortical functions.
A separate study of children with developmental language disorder (DLD) — defined as failure of normal language development despite normal nonverbal intelligence — found that tapping and pegboard performance with both hands was significantly impaired compared to controls. Handedness did not differ from controls. This motor impairment in DLD is noted here only because the disease description overlaps with Rett syndrome’s language and motor features, but the DLD study does not involve MECP2 mutation or Rett syndrome patients.
No drug treatment is tested or proposed in any of these abstracts. What is missing for Rett syndrome is not a candidate drug from these papers, but rather a clear understanding of which synaptic or aminergic targets are amenable to intervention, and clinical trial designs that account for the age-dependent and regressive course of the disorder. Patient stratification by mutation type, disease stage, and measurable biomarkers such as neurotransmitter levels or synaptic function remains absent from the evidence presented.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractRett syndrome (RTT), a neurodevelopmental condition characterized by delayed-onset loss of spoken language and the development of distinctive hand stereotypies, affects approximately 1 in 10,000 live female births. Clinical diagnosis has been based on symptoms such as loss of acquired purposeful hand skills, autistic behaviors, motor dysfunctions, seizure disorders, and gait abnormalities. RTT is a genetic disease and is caused almost exclusively by mutations in the X-linked gene, MECP2, to produce a phenotype that is thought to be primarily of neurological origin. Clinical reports show RTT patients to have a smaller brain volume, especially in the cerebral hemispheres, and alterations in various neurotransmitter systems, including acetylcholine, dopamine, serotonin, glutamate, substance P, and various trophic factors. Because of its monogenetic characteristic, disruption of Mecp2 is readily recapitulated in mice to produce a prominent RTT-like phenotype and provide an excellent platform for understanding the pathogenesis of RTT. As shown in human studies, Mecp2 mutants also display subtle alterations in neuronal morphology, including smaller cortical neurons with a higher-packing density and reduced dendritic complexity. Neurophysiological studies in Mecp2-mutant mice consistently report alterations in synaptic function, notably, defects in synaptic plasticity. These data suggest that RTT might be regarded as a synaptopathy (disease of the synapse) and thus potentially amenable to rational therapeutic intervention.
AbstractRett syndrome is a unique neurodevelopmental disorder, with onset of hypotonia, autistic tendency, and abnormalities of fine finger movements and gross movements of the arms in early infancy. Clinical features include specific age-dependent symptoms. Studies of early and late signs correlated locomotive dysfunction to language disability and stereotypy to regression of higher cortical functions. Studies of sleep parameters revealed early hypofunction of brainstem aminergic neurons and late occurrence of hypofunction of dopaminergic neurons, followed by receptor supersensitivity. The syndrome's pathophysiology suggests that early hypofunction of aminergic neurons interferes with the development of higher neuronal systems. Particular symptoms surface at different ages throughout the natural course of Rett syndrome, with regressional and static periods.
Motor Performance and Handedness in Children with Developmental Language Disorder
AbstractDevelopmental language disorder (DLD) is diagnosed when there is a failure of normal language development in a child with normal nonverbal intelligence. The discussion about additional or causal deficits is controversial. In this study a computer-based motor performance series with a tapping, aiming and pegboard movement task and an additional paper-pencil handedness test were applied to a group of children with DLD of the phonologic-syntactic subtype and with normal nonverbal intelligence to describe the additional motor problems. Furthermore we examined whether our DLD children showed a different handedness. Tapping and pegboard with both hands were significantly impaired in our DLD children. Overall our DLD children did not show a different handedness than the control group.
American Journal of Medical Genetics Part A · 2020 · 5 citations
49,<scp>XXXXY</scp>syndrome: A study of neurological function in this uncommon X and Y chromosomal disorder
Abstract49,XXXXY is a rare chromosomal variation characterized by deficits in motor, language, and cognitive domains. This study reports on the neurological function and dysmorphic features in the largest cohort to date. Seventy-two boys with 49,XXXXY were evaluated on a variety of domains including a neurological examination and neuromotor assessments including the Beery Buktenica Developmental Test of Visual-Motor Integration, Sixth Edition, the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III), and the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition. Results supported previous literature by describing high occurrences of truncal and extremity hypotonia, which significantly impacts on motor milestones and ambulation in this population. The boys presented with dysmorphic features including epicanthal folds, frontal bossing, and synophrys. Visual perception skills were mildly impaired and cranial nerves were typically intact, however capabilities in motor coordination and fine motor precision were greatly delayed, supporting deficits in refined and controlled hand movements versus widespread visual deficits. Preschool boys treated with testosterone replacement had significantly increased scores when compared to the untreated group on the BSID-III Psychomotor Development Index, further supporting previous research indicating that testosterone replacement may have a positive impact on neurodevelopmental outcomes in males with additional X chromosomes. Boys with 49,XXXXY may benefit from hormonal treatment in conjunction with early intervention services to address their significant motor deficits.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
